Retatrutide Tracker.
Up to 24.2% mean weight loss at 48 weeks in its Phase 2 trial — the largest reduction reported for any incretin medication to date. Retatrutide is in clinical trials — here's what the published data says, and how GLP AI is ready for it.
Retatrutide is not FDA-approved. Investigational — Phase 3 trials (TRIUMPH program). Not FDA-approved. Everything here comes from published trials, cited below — education, not medical advice. Products sold as "retatrutide" outside clinical trials are unregulated.
Retatrutide, from the published data.
Triple agonist — activates GIP, GLP-1, and glucagon receptors (one more than tirzepatide's dual mechanism). Weekly injection (in trials).
| Phase 2 result (obesity) | 17.5% mean weight loss at 24 weeks; 24.2% at 48 weeks on the highest dose (12 mg) |
| Trial doses | 1 mg to 12 mg weekly, with stepped escalation |
| Side-effect profile | GI-first, like approved GLP-1s — nausea, diarrhea, vomiting, constipation; dose-dependent |
| Status | Phase 3 TRIUMPH trials underway; no FDA approval or launch date announced |
Sources: Phase 2 obesity trial — Jastreboff et al., NEJM 2023 · TRIUMPH-3 Phase 3 trial record (ClinicalTrials.gov)
How Retatrutide differs from today's GLP-1s.
Semaglutide activates one receptor (GLP-1); tirzepatide two (GIP + GLP-1); retatrutide three (GIP + GLP-1 + glucagon). The added glucagon activity may raise energy expenditure — one hypothesis for its record trial numbers. Trial results across different studies aren't directly comparable.
GLP AI is retatrutide-ready.
Trial participants can track retatrutide in GLP AI today via custom medications — doses, meals with the 0–100 GLP-1 Meal Score, side effects, and weight on one timeline. When retatrutide launches, dose schedules and the medication level chart arrive with it, and your history carries over from whatever you track now.
Retatrutide — FAQs.
What is Retatrutide?+
Retatrutide is an investigational medication from Eli Lilly — triple agonist — activates GIP, GLP-1, and glucagon receptors (one more than tirzepatide's dual mechanism). Investigational — Phase 3 trials (TRIUMPH program). Not FDA-approved. This page is education from published trials, not medical advice.
Can I get Retatrutide now?+
Only through a clinical trial. Retatrutide is not FDA-approved, and products sold under its name outside trials are unregulated and potentially unsafe. Talk to your doctor about trial eligibility or approved alternatives.
Can GLP AI track Retatrutide?+
Yes — GLP AI supports custom medications, so trial participants can track doses, meals, side effects, and weight today. When Retatrutide launches, first-class support (dose schedules, level chart) arrives with it.
What should I use while waiting for Retatrutide?+
That's a conversation for your doctor — approved options include semaglutide (Ozempic, Wegovy, Rybelsus) and tirzepatide (Mounjaro, Zepbound). Whichever you're prescribed, GLP AI tracks it, and switching later keeps your history intact.
Is retatrutide approved by the FDA?+
No. Retatrutide is investigational — Phase 3 trials (the TRIUMPH program) are underway, and no approval date has been announced. Anything sold as "retatrutide" outside a clinical trial is unregulated and untested.
How much weight loss did retatrutide show in trials?+
In its Phase 2 obesity trial (NEJM 2023), the highest dose (12 mg weekly) produced 24.2% mean weight loss at 48 weeks — with the curve still declining at the study's end. Phase 3 will test whether that holds at scale.
Is retatrutide stronger than tirzepatide?+
Cross-trial comparisons are unreliable, but retatrutide's Phase 2 average (24.2% at 48 weeks) exceeds tirzepatide's Phase 3 average (20.9% at 72 weeks). Its triple-receptor mechanism is one hypothesis. Head-to-head data doesn't exist yet.
Go further with GLP AI.
Track it once. Understand it forever.
Start tracking today — your history carries into whatever comes next.